Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.93M | -5.65M | -5.30M | -4.44M | -5.45M |
| Total Depreciation and Amortization | 35.50K | -110.00K | 49.50K | 52.30K | 55.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 345.80K | 371.60K | 290.10K | 292.90K | 82.50K |
| Change in Net Operating Assets | 539.20K | 546.80K | 611.50K | -176.40K | 194.40K |
| Cash from Operations | -6.01M | -4.85M | -4.34M | -4.28M | -5.12M |
| Capital Expenditure | 0.00 | -3.40K | -5.90K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -3.40K | -5.90K | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 31.66M | -- | 4.99M | 5.79M | 2.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.66M | -- | 4.99M | 5.79M | 2.25M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.65M | -4.85M | 641.70K | 1.51M | -2.86M |